TY  - JOUR
A1  - Liebers, Nora
A1  - Duell, Johannes
A1  - Fitzgerald, Donnacha
A1  - Kerkhoff, Andrea
A1  - Noerenberg, Daniel
A1  - Kaebisch, Eva
A1  - Acker, Fabian
A1  - Fuhrmann, Stephan
A1  - Leng, Corinna
A1  - Welslau, Manfred
A1  - Chemnitz, Jens
A1  - Middeke, Jan-Moritz
A1  - Weber, Thomas
A1  - Holtick, Udo
A1  - Trappe, Ralf
A1  - Pfannes, Roald
A1  - Liersch, Ruediger
A1  - Spoer, Christian
A1  - Fuxius, Stefan
A1  - Gebauer, Niklas
A1  - Caillé, Léandra
A1  - Geer, Thomas
A1  - Koenecke, Christian
A1  - Keller, Ulrich
A1  - Claus, Rainer
A1  - Mougiakakos, Dimitrios
A1  - Mayer, Stephanie
A1  - Huettmann, Andreas
A1  - Pott, Christiane
A1  - Trummer, Arne
A1  - Wulf, Gerald
A1  - Brunnberg, Uta
A1  - Bullinger, Lars
A1  - Hess, Georg
A1  - Mueller-Tidow, Carsten
A1  - Glass, Bertram
A1  - Lenz, Georg
A1  - Dreger, Peter
A1  - Dietrich, Sascha
T1  - Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
JF  - Blood Advances
N2  - The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-369173
VL  - 5
ER  -